PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) ophthalmic solution
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) ophthalmic solution, covering 2022-01-19 to 2022-01-19. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension [Phase 3]